US20060035856A1 - Purified polypeptides having IL-13 receptor activity - Google Patents

Purified polypeptides having IL-13 receptor activity Download PDF

Info

Publication number
US20060035856A1
US20060035856A1 US11/183,599 US18359905A US2006035856A1 US 20060035856 A1 US20060035856 A1 US 20060035856A1 US 18359905 A US18359905 A US 18359905A US 2006035856 A1 US2006035856 A1 US 2006035856A1
Authority
US
United States
Prior art keywords
receptor
antibody
seq
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/183,599
Other languages
English (en)
Inventor
Daniel Caput
Pascual Ferrara
Patrick Laurent
Natalio Vita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9485198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060035856(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to US11/183,599 priority Critical patent/US20060035856A1/en
Publication of US20060035856A1 publication Critical patent/US20060035856A1/en
Assigned to SANOFI reassignment SANOFI ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CAPUT, DANIEL, FERRARA, PASCUAL, LAURENT, PATRICK, VITA, NATALIO
Assigned to SANOFI-SYNTHELABO reassignment SANOFI-SYNTHELABO ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SANOFI
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SANOFI-SYNTHELABO
Assigned to SANOFI reassignment SANOFI CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SANOFI-AVENTIS
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
US11/183,599 1995-12-06 2005-07-15 Purified polypeptides having IL-13 receptor activity Abandoned US20060035856A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/183,599 US20060035856A1 (en) 1995-12-06 2005-07-15 Purified polypeptides having IL-13 receptor activity

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9514424A FR2742156A1 (fr) 1995-12-06 1995-12-06 Polypeptide recepteur de l'il-13
FR95/14424 1995-12-06
PCT/FR1996/001756 WO1997020926A1 (fr) 1995-12-06 1996-11-07 Polypeptide recepteur de l'il-i3
US7781798A 1998-09-14 1998-09-14
US11/183,599 US20060035856A1 (en) 1995-12-06 2005-07-15 Purified polypeptides having IL-13 receptor activity

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/FR1996/001756 Division WO1997020926A1 (fr) 1995-12-06 1996-11-07 Polypeptide recepteur de l'il-i3
US7781798A Division 1995-12-06 1998-09-14

Publications (1)

Publication Number Publication Date
US20060035856A1 true US20060035856A1 (en) 2006-02-16

Family

ID=9485198

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/182,384 Expired - Fee Related US7928073B2 (en) 1995-12-06 2005-07-15 Purified polypeptides having IL-13 receptor activity
US11/183,599 Abandoned US20060035856A1 (en) 1995-12-06 2005-07-15 Purified polypeptides having IL-13 receptor activity
US11/185,230 Abandoned US20050282216A1 (en) 1995-12-06 2005-07-18 Purified polypeptides having IL-13 receptor activity
US13/027,425 Expired - Fee Related US8318910B2 (en) 1995-12-06 2011-02-15 IL-13 receptor antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/182,384 Expired - Fee Related US7928073B2 (en) 1995-12-06 2005-07-15 Purified polypeptides having IL-13 receptor activity

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/185,230 Abandoned US20050282216A1 (en) 1995-12-06 2005-07-18 Purified polypeptides having IL-13 receptor activity
US13/027,425 Expired - Fee Related US8318910B2 (en) 1995-12-06 2011-02-15 IL-13 receptor antibodies

Country Status (19)

Country Link
US (4) US7928073B2 (fr)
EP (1) EP0876482B1 (fr)
JP (3) JP3415162B2 (fr)
AR (2) AR004860A1 (fr)
AT (1) ATE234922T1 (fr)
AU (1) AU7576096A (fr)
BR (1) BR9611697B1 (fr)
CA (1) CA2238893C (fr)
DE (1) DE69626859T2 (fr)
DK (1) DK0876482T3 (fr)
ES (1) ES2192620T3 (fr)
FR (1) FR2742156A1 (fr)
MX (1) MX9804419A (fr)
MY (1) MY123740A (fr)
NO (3) NO324775B1 (fr)
PT (1) PT876482E (fr)
TW (1) TW565570B (fr)
WO (1) WO1997020926A1 (fr)
ZA (1) ZA9610238B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
US11352402B2 (en) 2013-09-24 2022-06-07 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
EP0907730B1 (fr) * 1995-10-23 2009-10-07 Zenyth Operations Pty Ltd Recepteur d'hematopoietine et sequences genetiques le codant
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
EP0812913A3 (fr) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation Récepteur HR-1 appartenant la famille des récepteurs de cytokin
WO1998010638A1 (fr) * 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Molecules d'interet therapeutique
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2235420A1 (fr) 1998-06-17 1999-12-17 Paolo Renzi Oligonucleoside antisens pour traiter ou prevenir les maladies atopiques et la proliferation de cellules neoplastiques
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
MXPA01006006A (es) 1998-12-14 2004-08-12 Genetics Inst Cadena receptora de citocina.
US20020197266A1 (en) * 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
EP1268794A2 (fr) * 2000-04-07 2003-01-02 Heska Corporation Compositions et methodes en rapport avec des recepteurs canins d'immunoglobuline g (igg) et d'il-13
CA2491320A1 (fr) 2002-07-15 2004-01-22 Wyeth Techniques et compositions permettant de moduler la fonction et le developpement de cellules assistantes (t<sb>h</sb>)
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
BRPI0517387A8 (pt) 2004-10-29 2017-07-11 Topigen Pharmaceuticals Inc Oligonucleotídeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas
WO2006055638A2 (fr) 2004-11-17 2006-05-26 Abgenix, Inc. Anticorps monoclonaux entierement humains diriges contre l'il-13
GB0615881D0 (en) * 2006-08-10 2006-09-20 Univ Southampton Novel peptide for treatment of asthma
MX2009011366A (es) * 2007-04-23 2009-11-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13.
WO2014152361A1 (fr) 2013-03-15 2014-09-25 Wake Forest University Health Sciences Anticorps dirigés contre l'il-13ra2 humaine et canine
NZ756749A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6911530B1 (en) * 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
US9732133B2 (en) 2012-01-27 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic IL-13 polypeptides
US10227389B2 (en) 2012-01-27 2019-03-12 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic IL-13 polypeptides
US11084858B2 (en) 2012-01-27 2021-08-10 The Board of Trustees of the Leland Stanford Junior University Stanford, CA Therapeutic IL-13 polypeptides
US11352402B2 (en) 2013-09-24 2022-06-07 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof

Also Published As

Publication number Publication date
ZA9610238B (en) 1998-06-05
DE69626859T2 (de) 2003-12-24
US20050282216A1 (en) 2005-12-22
NO331148B1 (no) 2011-10-24
US20110201029A1 (en) 2011-08-18
MX9804419A (es) 1998-09-30
JP2005323595A (ja) 2005-11-24
ATE234922T1 (de) 2003-04-15
NO324775B1 (no) 2007-12-10
NO20092994L (no) 1998-08-05
EP0876482B1 (fr) 2003-03-19
NO328197B1 (no) 2010-01-04
WO1997020926A1 (fr) 1997-06-12
MY123740A (en) 2006-06-30
TW565570B (en) 2003-12-11
AR004860A1 (es) 1999-03-10
JP4185070B2 (ja) 2008-11-19
CA2238893A1 (fr) 1997-06-12
JPH11511028A (ja) 1999-09-28
ES2192620T3 (es) 2003-10-16
PT876482E (pt) 2003-07-31
CA2238893C (fr) 2013-10-08
JP2003180382A (ja) 2003-07-02
DE69626859D1 (de) 2003-04-24
JP3415162B2 (ja) 2003-06-09
AU7576096A (en) 1997-06-27
NO982550D0 (no) 1998-06-04
US7928073B2 (en) 2011-04-19
DK0876482T3 (da) 2003-07-21
US20060035855A1 (en) 2006-02-16
NO20074034L (no) 1998-08-05
FR2742156A1 (fr) 1997-06-13
NO982550L (no) 1998-08-05
AR056723A2 (es) 2007-10-17
JP3737793B2 (ja) 2006-01-25
BR9611697A (pt) 1999-02-17
US8318910B2 (en) 2012-11-27
BR9611697B1 (pt) 2013-09-17
EP0876482A1 (fr) 1998-11-11

Similar Documents

Publication Publication Date Title
US8318910B2 (en) IL-13 receptor antibodies
AU760224B2 (en) Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
Marchese et al. Cloning of human genes encoding novel G protein-coupled receptors
US7972833B2 (en) Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
JP5015404B2 (ja) 可溶性ｚｃｙｔｏｒ１１サイトカイン受容体
US7557187B2 (en) Purified SR-p70 protein
US20020102639A1 (en) Evi27 gene sequences and protein encoded thereby
US20020160451A1 (en) Novel orphan receptors
JP2002535979A (ja) 新規ｒｇｓ含有分子およびその使用
US7081528B2 (en) Isolated nucleic acid molecules encoding T cell derived inducible factors
JP3598386B2 (ja) インターロイキン−９レセプタの遺伝暗号を指示する核酸配列，又は，前記核酸配列を相補する核酸配列
US6743604B1 (en) Substances and their uses
AU753400C (en) Orphan receptors
AU764484B2 (en) Orphan cytokine receptor
EP1152059A1 (fr) Nouvelle proteine de type recepteur de cytokines
JPH10313870A (ja) 新規なｂ細胞表面タンパク質及びこれをコードするｄｎａ

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS, FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:SANOFI-SYNTHELABO;REEL/FRAME:028753/0295

Effective date: 20040820

Owner name: SANOFI-SYNTHELABO, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SANOFI;REEL/FRAME:028748/0888

Effective date: 20000120

Owner name: SANOFI, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAPUT, DANIEL;FERRARA, PASCUAL;LAURENT, PATRICK;AND OTHERS;SIGNING DATES FROM 19980706 TO 19980707;REEL/FRAME:028748/0620

AS Assignment

Owner name: SANOFI, FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:SANOFI-AVENTIS;REEL/FRAME:028775/0284

Effective date: 20110511

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION